Traquina P, Morandi M, Contorni M, Van Nest G
Chiron Corporation, Emeryville, California, USA.
J Infect Dis. 1996 Dec;174(6):1168-75. doi: 10.1093/infdis/174.6.1168.
The effect of the proprietary adjuvant MF59 on the immunogenicity of a recombinant hepatitis B virus (HBV) vaccine, PreS2+SAg, was investigated in baboons. The magnitude and duration of the antibody response to hepatitis B surface antigen (anti-HBs) induced by the HBV/MF59 vaccine was compared with the same antigen combined with alum and with two licensed alum vaccines. After one immunization, the HBV/MF59 vaccine generated anti-HBs titers >10 mIU/mL in a greater proportion of animals, and mean titers were 26- to 84-fold higher than titers from alum vaccines. After a third immunization, the HBV/MF59 vaccine generated titers 38- to 127-fold higher than alum vaccines. Seven months after the third immunization, HBV/MF59 elicited titers 75- to 472-fold higher than alum vaccines. The dramatic immune response elicited by HBV/MF59 in baboons suggests that MF59 may be a desirable adjuvant for use in improved HBV vaccines for humans.
在狒狒中研究了专利佐剂MF59对重组乙肝病毒（HBV）疫苗PreS2+SAg免疫原性的影响。将HBV/MF59疫苗诱导的针对乙肝表面抗原（抗-HBs）的抗体反应的强度和持续时间，与相同抗原与明矾组合的情况以及两种已获许可的明矾疫苗进行了比较。一次免疫后，HBV/MF59疫苗在更大比例的动物中产生了>10 mIU/mL的抗-HBs滴度，平均滴度比明矾疫苗高26至84倍。第三次免疫后，HBV/MF59疫苗产生的滴度比明矾疫苗高38至127倍。第三次免疫七个月后，HBV/MF59引发的滴度比明矾疫苗高75至472倍。HBV/MF59在狒狒中引发的显著免疫反应表明，MF59可能是用于改进人类HBV疫苗的理想佐剂。
